We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Boehringer Extends Scope of Collaboration with Evotec into Screening Services
News

Boehringer Extends Scope of Collaboration with Evotec into Screening Services

Boehringer Extends Scope of Collaboration with Evotec into Screening Services
News

Boehringer Extends Scope of Collaboration with Evotec into Screening Services

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Boehringer Extends Scope of Collaboration with Evotec into Screening Services "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Evotec AG has announced that Boehringer Ingelheim has extended the scope of its collaboration with Evotec. In addition to the substantial discovery programme to jointly identify and develop therapeutics acting on G-Protein Coupled Receptors. 

Boehringer research sites in Biberach (Germany) and Laval (Canada) will now collaborate with Evotec under a fee-for-service agreement.

For selected Boehringer target proteins, Evotec will apply its skills in biochemical and cellular assay development as well as in ultra-high-throughput screening using its proprietary FCS+plus detection platform to rapidly and accurately identify promising hit molecules from Boehringer's and Evotec's compound libraries. Active compounds will be further progressed by Boehringer to develop treatments for different diseases.

Dr Mark Ashton, Executive Vice President Business Development Services at Evotec, commented, "We are extremely delighted to further expand our collaboration with Boehringer Ingelheim. Boehringer is a successful pharmaceutical company which places significant emphasis on innovative approaches to drug discovery."

"The fact that they have chosen Evotec as a partner for assay development and screening services is a strong endorsement of the high quality results we deliver in our ongoing collaboration in the field of drug discovery."

Professor Mikael Dolsten, Head of Corporate Division Pharma Research/Discovery, Boehringer Ingelheim GmbH, said, "Evotec has a strong track record in performing uHTS screens and handling large compound pools in complex assays."

"Evotec's proprietary detection technology also offers sensitive and robust systems for hit identification. These skills together with the experience we have made in our ongoing collaboration have convinced us that Evotec is the ideal partner for our drug finding programmes."

Advertisement